Nuclear translocation of SMAD2/3, core transcription factors of TGFβ signaling, is critical for hepatic stellate cell (HSC) differentiation into metastasis-promoting myofibroblasts. SMAD2/3 have multiple coactivators, including WW domain-containing transcription regulator protein 1 (WWTR1 or TAZ) and p300 acetyltransferase. In the nucleus, TAZ binds to SMAD2/3 to prevent SMAD2/3 nuclear export. However, how TAZ and SMAD2/3 enter the nucleus remains poorly understood because neither contains a nuclear localization signal (NLS), an amino acid sequence tagging proteins for nuclear transport. P300 is a NLS-containing large scaffold protein so we hypothesized that SMAD2/3 and TAZ may undergo nuclear import through complexing with p300. Coimmunoprecipitation, immunofluorescence, and nuclear fractionation assays revealed that TGFβ1 promoted binding of SMAD2/3 and TAZ to p300 and that p300 inactivation disrupted TGFβ1-mediated SMAD2/3 and TAZ nuclear accumulation. Deleting the p300 NLS blocked TGFβ1-induced SMAD2/3 and TAZ nuclear transport. Consistently, p300 inactivation suppressed TGFβ1-mediated HSC activation and transcription of genes encoding tumor-promoting factors, such as CTGF, TNC, POSTN, PDGFC, and FGF2, as revealed by microarray analysis. ChIP-qPCR showed that canonical p300-mediated acetylation of histones also facilitated transcription in response to TGFβ1 stimulation. Interestingly, although both TGFβ1- and stiffness-mediated HSC activation require p300, comparison of gene expression datasets revealed that transcriptional targets of TGFβ1 were distinct from those of stiffness-p300 mechanosignaling. Lastly, in tumor/HSC coinjection and intrasplenic tumor injection models, targeting p300 of activated-HSC/myofibroblasts by C646, shRNA, or cre-mediated gene disruption reduced tumor and liver metastatic growth in mice. Conclusion: P300 facilitates TGFβ1-stimulated HSC activation by both non-canonical (cytoplasm-to-nucleus shuttle for SMAD2/3 and TAZ) and canonical (histone acetylation) mechanisms. P300 is an attractive target for inhibiting HSC activation and the prometastatic liver microenvironment.